MAGEA4 (melanoma-associated antigen 4) is very similar to MAGEA3. It is expressed only in immune privileged reproductive tissues (primary spermatocytes, spermatogonia in male and placental trophoblast in female). As a tumor-specific protein, MAGEA4 also expresses exclusively and aberrantly on multiple tumors (melanoma, non-small cell lung cancer, hematologic malignancies, etc.) excluding most normal somatic cells, and plays an active role in driving cancer progression and indicates bad prognosis. Therefore, MAGEA4 is an attractive immunotherapeutic target for the anti-MAGEA4 CAR-T cell therapy.
Structures of MAGEA4
Diagram created by Creative Biolabs based on data from PloS one 11.2 (2016): e0148762
Anti-MAGEA4 CAR-T Cell Therapy
Since MAGEA4 plays a critical role in multiple human malignancies, several phase 1 clinical trials (NCT02239861, NCT02291848, NCT01333046) try to apply tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes for the treatment of multiple human malignancies. Creative Biolabs is dedicated to assisting researchers to initiate and develop the cutting-edge anti-MAGEA4 CAR-T cell therapy.
Animal Models for in vivo Study of anti-MAGEA4 CAR-T Cell Therapy
Creative Biolabs offers researchers almost all the animal models generated from the major techniques including the conventional carcinogen-induced models, the mosaic transposon- or virus-induced models, the transgenic models and the subcutaneous or patient-derived xenograft models for a variety of human malignancies. In addition, Creative Biolabs also assists customers in creating clinically relevant animal models including but not limited to the above categories. You request, Creative Biolabs offers the best.
In vivo Assay Parameters and Techniques
At Creative Biolabs, we offer the most exquisite and comprehensive service platform for preclinical MAGEA4 CAT-T cell therapy research.
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
Creative Biolabs outperforms the entire biotechnological community to back researchers with every resource for establishing the most reliable and subtle animal models in advance to help the customer achieve incredible disproportionate results and exponentially greater value. Creative Biolabs assists researchers in making the scientific history.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE